Extended Data Fig. 7: TXNRD1 is required for SASP function in vivo.
a, TOV21G ovarian cancer cell growth in conditioned medium collected from control and senescent IMR90 cells with or without TXNRD1 knockdown or Tri-1 treatment. After 7 days of incubation, the cell numbers were determined and normalized to the numbers of the cells cultured in conditioned media collected from control proliferating IMR90 cells. Data represent mean ± s.e.m. n = 3 biologically independent experiments unless otherwise stated. P-values were calculated using a two-tailed t test. b, c, TOV21G and oncogene-induced senescent IMR90 cells with or without TXNRD1 inhibition were subcutaneously co-injected into the right dorsal flank of 6–8-week-old NSG female mice (n = 5 biologically independent mice per group). Shown are images of tumors dissected in the indicated groups at the end of experiments (b). Tumor growth in the indicated treatment groups was measured at the indicated time points (c). Data represent mean ± s.e.m. d, Validation of Txnrd1 knockdown by immunostaining in mouse NIH 3T3 cells. Arrows point to dsRed-expressing shRen control, shTxnrd1 #1 and shTxnrd1 #2. Scale bars = 10 μm. The experiment was repeated twice with similar results.
